Effects of Jiedu-jiangzhuo Granules on Gut Microbiota and TLR4/NF-κB Pathway of Metabolic Syndrome Rats
HAO Qiu-hong1, YANG Xi2, YANG Yan-ping3, ZHOU Xin3*
1. Jinzhong Food and Drug Inspection and Testing Center, Jinzhong 030600, China; 2. Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan 030000,China; 3. Department of Pathophysiology,Shanxi Medical University, Taiyuan 030001, China
Abstract：OBJECTIVE To explore the effects of Jiedu-jiangzhuo granules on gut microbiota of metabolic syndrome rats and TLR4/NF-κB pathway. METHODS SD rats were randomly divided into normal control group, model group, metformin group, experimental high-dose of Jiedu-jiangzhuo granules 2.4 g·kg-1·d-1 group and experimental low-dose of Jiedu-jiangzhuo granules 1.2 g·kg-1·d-1 group, with 12 rats in each group. Except for rats in the control group, the other rats were fed with high-fat/ sugar/salt diet for 12 weeks. When fed for 8 weeks, the rats in metformin group (0.103 g·kg-1·d-1), experimental high-dose group (2.4 g·kg-1·d-1) or experimental low-dose group (1.2 g·kg-1·d-1) were simultaneously gavaged with metformin or Jiedu-jiangzhuo granules for 4 weeks. Body weight, serum lipid indexes and lipopolysaccharide(LPS) were determined by biochemical method, liver coefficient and epididymal fat tissue coefficient of rats were detected. Total genomic DNA of gut microbiota was extracted from fecal samples, then DNA library was built. Community structures of fecal microbes and α-diversity were sequenced on the Illumina Miseq platform. RESULTS At the end of experiment, the body weight, LPS, serum total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C) and fasting blood glucose(FBG) of rats in experimental high-dose group were lower than those in the model group and higher than those in the control group (P<0.05), and HDL-C was also higher in experimental high-dose group than that in the model group, but lower than that in the control group (P<0.05); but there was no statistical difference in TC, TG, LDL-C, HDL-C and FBG levels between experimental high-dose group and metformin group (P>0.05). The liver coefficient and epididymal fat tissue coefficient of rats in experimental high-dose group were lower than those in the model group (P<0.05), but there was no statistical difference between experimental high-dose group and control group or metformin group (P>0.05). Besides, the NF-κB, IL-6, TNF-α levels of rats inexperimental high-dose group were lower than those in the model group, metformin group or low-dose group (P<0.05), but almost the same as those in the control group (P>0.05). Chaol index of gut microbiota was higher than that in the other four groups (P<0.05), but there was no statistical difference of Shannon diversity among the five groups (P>0.05). The ratios of Firmicutes, Proteobacteria, Actinobacteria, Tenericutes and Prevotella, Phascolarctobacterium in experimental high-dose group were lower than those in model group (P<0.05), meanwhile the ratios of Bacteroidetes, Paraprevotella and Bacteroides were higher than those in model group (P<0.05). Finally, TLR4 and NF-κB proteins in colonic tissues of rats in experimental high-dose group were lower than those in model group(P<0.05). CONCLUSIONS There are significant evidences that Jiedu-jiangzhuo granules could play a role in lower of weight gain and blood lipids in metabolic syndrome rats by adjusting the gut microbiota and TLR4/NF-κB pathway.
郝秋红, 杨晞, 杨艳萍, 周鑫. 解毒降浊颗粒对代谢综合征SD大鼠肠道菌群结构及TLR-4/NF-κB信号通路的影响[J]. 中国药学杂志, 2020, 55(8): 595-602.
HAO Qiu-hong, YANG Xi, YANG Yan-ping, ZHOU Xin. Effects of Jiedu-jiangzhuo Granules on Gut Microbiota and TLR4/NF-κB Pathway of Metabolic Syndrome Rats. Chinese Pharmaceutical Journal, 2020, 55(8): 595-602.
MENDRICK D L, DIEHL A M, TOPOR L S, et al. Metabolic syndrome and associated diseases: from the bench to the clinic[J]. Toxicol Sci, 2018, 162(1):36-42.
[2]
DE GROOT P F, FRISSEN P F, CLERCQ N C, et al. Fecal microbiota transplantation inmetabolicsyndrome: history, present and future[J]. Gut Microbes, 2017, 8(3):253-267.
[3]
HUANG F, LIU T H, QIAO L L, et al. Correlation between metabolicsyndrome treated with TCM and gut microbiota[J]. Shanxi J Tradit Chin Med (陕西中医), 2017, 38(9):1270-1272.
[4]
ZHOU X, HAN D W, XU R L, et al. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet[J]. PLoS One, 2014, 9(12):115-148.
[5]
HU J, LIN S, ZHENG B, et al. Short-chain fatty acids in control of energy metabolism[J]. Crit Rev Food Sci Nutr, 2018, 58(8):1243-1249.
[6]
DESAI M S, MATHUR B, EBLIMIT Z, et al. Bile acid excess induces cardiomyopathy andmetabolic dysfunctions in the heart[J]. Hepatology, 2017, 65(1):189-201.
[7]
JIALAL I, RAJAMANI U. Endotoxemia of metabolic syndrome: a pivotal mediator of Meta-inflammation[J]. Metab Syndr Relat Disord, 2014, 12(9):454-456.
[8]
MC CRACKEN E, MONAGHAN M, SREENIVASAN S. Pathophysiology of the metabolic syndrome[J]. Clin Dermatol, 2018, 36(1):14-20.
[9]
SEEDORF H, GRIFFIN N W, RIDAURA V K, et al. Bacteria from diverse habitats colonize and compete in the mouse gut[J]. Cell, 2014, 159(2):253-266.
[10]
PONZIANI F R, PECERE S, GASBARRINI A, et al. Physiology and pathophysiology of liver lipid metabolism[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(8):1055-1067.
[11]
FEDERICO A, DALLIO M, DI SARNO R, et al. Gut microbiota, obesity and metabolicdisorders[J]. Minerva Gastroenterol Dietol, 2017, 63(4):337-344.
[12]
BULLMAN S, PEDAMALLU C S, SICINSKA E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science,2017,358(6369): 1443-1448.
[13]
DE CLERCQ N C, FRISSEN M N, GROEN A K, et al. Gut microbiota and the gut-brain axis: new insights in the pathophysiology of metabolic syndrome[J]. Psychosom Med, 2017, 79(8):874-879.
[14]
CHOUDHURY S, GHOSH S, GUPTA S, et al. Inflammation-induced ROS generation causes pancreatic cell death through modulation of Nrf2/NF-κB and SAPK/JNK pathway[J]. Free Radic Res, 2015, 49(11):1371-1383.
[15]
WANG S Y, ZHANG J. Research of Yiqi Yangyin Huoxue method on insulin resistance of type 2 diabetes[J]. Acta Chin Med(中医研究), 2016, 29(3): 75-78.
[16]
XU Y, HOU B H, LI B. Intervention effect of gegen Shanzha decoction combining with TCM physique recuperation on metabolism syndrome[J]. Chin J Tradit Med Sci Technol(中国中医药科技), 2014, 21(4):362-364.
[17]
WANG H M, GE B Y, WANG Y, et al. Influence of Chaiqi decoction on serum ICAM-1 and VCAM-1 levels in the rat model of metabolic syndrome[J]. Mod Chin Med(中国现代中药), 2018, 20(10): 1235-1241.
2020, Vol. 55 
